{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:48:29Z","timestamp":1793414909795,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Jin Hua Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.05.031","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:04:45Z","timestamp":1748225085000},"page":"1569-1573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["How to Adjust Asthma Management Once Asthma Is Controlled on Long-Term Biologic Therapy"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.05.031_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.05.031_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.031_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.031_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2024.04.031","article-title":"Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study","volume":"133","author":"Brightling","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.031_bib6","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.031_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.05.031_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00017-2020","article-title":"Low adherence to inhaled corticosteroids\/long-acting \u03b22-agonists and biologic treatment in severe asthmatics","volume":"6","author":"Caminati","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.05.031_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib10","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib11","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib12","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.jaip.2024.08.008","article-title":"Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION","volume":"12","author":"Wechsler","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.031_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03226-2021","article-title":"Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study","volume":"60","author":"Menzies-Gow","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.031_bib15","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaip.2023.03.009","article-title":"Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy","volume":"11","author":"Louis","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.031_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.05.031_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/jdv.20534","article-title":"Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how?","volume":"39","author":"Jacobson","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.05.031_bib20","article-title":"Successful treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a case report","volume":"15","author":"Toscano Pena","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2025.05.031_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a european collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2025.05.031_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2025.05.031_bib23","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.031_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.05.031_bib25","doi-asserted-by":"crossref","first-page":"A50","DOI":"10.1016\/j.chest.2023.07.090","article-title":"Decreasing frequency of dupilumab is associated with stable asthma in select populations","volume":"164","author":"Garvey","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.05.031_bib26","author":"Gawel"},{"key":"10.1016\/j.jaip.2025.05.031_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.031_bib28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.031_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.05.031_bib30","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.031_bib31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.031_bib32","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jpm13111594","article-title":"Combination of biological therapy in severe asthma: where we are?","volume":"13","author":"Carriera","year":"2023","journal-title":"J Pers Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:40:28Z","timestamp":1755650428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825004969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825004969"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.031","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Adjust Asthma Management Once Asthma Is Controlled on Long-Term Biologic Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}